Close-up on a video camera screen, a woman stares into the lens.

Stay up to date on COVID-19. Learn more

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

July 16, 2024

Advocacy activities recap 2023

At first, engaging in advocacy initiatives involving government bodies, officials, drug agencies, and various stakeholders invested in improving the healthcare system or treatment accessibility may appear abstract or a little daunting. Nevertheless, numerous organizations, such as ours, are inherently suited to negotiate, influence and persuade those who have the authority[…]

Learn more

June 20, 2024

INESSS recommends including Tecvayli 

On June 5, 2024, the Institut national d’excellence en santé et en services sociaux (INESSS) formally recommended to the Minister that Tecvayli (teclistamab) be included in the list of medications at treatment centres for the treatment of patients with relapsed or refractory multiple myeloma, subject to specific conditions.   Read more here[…]

Learn more

June 20, 2024

Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

To date, identifying high-risk SMM patients remains an important clinical need. In this study, we present the 3-dimensional telomere profiling as a structural biomarker capable of stratifying SMM patients as a function of genomic instability Read more… […]

Learn more

May 24, 2024

CCTG Recruiting for a Patient Representative Volunteer Role

The Canadian Cancer Trial Group (CCTG) is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. We encourage applications from all qualified candidates and will accommodate applicants’ needs throughout all stages of the recruitment and[…]

Learn more

May 14, 2024

Tecvayli was recommended for reimbursement by the CDA-AMC! 

We are pleased to announce that on April 24th,TECVAYLI (teclistamab) was recommended for reimbursement by the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) of Canada’s Drug Agency (CDA-AMC)*– the first bispecific antibody for myeloma to be recommended for funding in Canada.   The pERC’s final decision states that contingent on a price reduction, teclistamab should[…]

Learn more

May 14, 2024

A Historic Turning Point: ODAC Unanimously Votes in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments

Minimal residual disease (MRD) testing has been recommended as an early endpoint in myeloma clinical trials by the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). If the recommendation is adopted by the FDA, it could lead to the accelerated approval of new treatments.  Read more… […]

Learn more
1 2 3 11

Myeloma Canada updates

 

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

July 16, 2024

Advocacy activities recap 2023

At first, engaging in advocacy initiatives involving government bodies, officials, drug agencies, and various stakeholders invested in improving the healthcare system or treatment accessibility may appear abstract or a little daunting. Nevertheless, numerous organizations, such as ours, are inherently suited to negotiate, influence and persuade those who have the authority[…]

Learn more

June 21, 2024

Martine Elias summarizes Real World Evidence (RWE) session at 2024 Myeloma Patients Europe Masterclass 

As proud members of Myeloma Patients Europe (MPe), Myeloma Canada attended – and presented at – MPe’s annual Masterclass this past May. The Masterclass is a one-and-a-half-day educational program designed to: increase the knowledge and skills of MPe’s members;  share the latest updates on myeloma and amyloidosis diagnosis, treatment and care;  discuss the[…]

Learn more

May 2, 2024

A round of applause for Martine and her new role! 

It is with great joy and pleasure that we announce the advancement of our well-regarded Executive Director, Martine Elias, to the distinguished position of CEO at Myeloma Canada.  Martine has been the driving force behind numerous achievements and advancements that have shaped Myeloma Canada into the leading organization it is today.[…]

Learn more

April 23, 2024

A Letter To the Decision Makers Whose Decisions Can Impact The Lives Of Canadians Living with Cancer, To Those With The Power to Reshape The Landscape of Cancer Care in Canada 

“Every hour in Canada tells a stark story. Twenty-seven individuals are thrust into the harsh reality of a cancer diagnosis, while ten others succumb to its merciless grip. Each day, 655 Canadians awaken to the daunting challenge ahead, while 238 bid farewell to their loved ones under the weight of[…]

Learn more

April 23, 2024

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action 

“Canada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to[…]

Learn more

April 4, 2024

Myeloma Canada releases 2023 science and research impact report

2023 was a banner year for Myeloma Canada’s science and research funding initiatives. We not only introduced 3 new grants, but we entered into 10 important partnerships, each one focused on advancing essential Canadian myeloma research. We are thrilled to announce that we are currently supporting more than 28 exciting[…]

Learn more
1 2 3 17